Krishnan Ramanathan
Overview
Explore the profile of Krishnan Ramanathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1275
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scheuermeyer F, Mattman A, Humphries K, Ramanathan K, Kaila K, Dodek P, et al.
CJEM
. 2024 Oct;
26(11):814-818.
PMID: 39467993
Background: For emergency department (ED) patients with cardiac chest pain, introduction of high-sensitivity troponin (hsTnT) pathways has been associated with reductions in length of stay of less than 1 h....
2.
Kingsley J, Kumarasamy N, Abrishamian L, Bonten M, Igbinadolor A, Mekebeb-Reuter M, et al.
Open Forum Infect Dis
. 2024 Jun;
11(6):ofae233.
PMID: 38854392
Background: The coronavirus disease 2019 (COVID-19) pandemic was characterized by rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, affecting viral transmissibility, virulence, and response to vaccines/therapeutics. EMPATHY...
3.
Hosseini F, Franco C, Whalen B, Taylor C, Sellers S, Khan N, et al.
Can J Cardiol
. 2023 Jul;
39(11):1584-1586.
PMID: 37517476
No abstract available.
4.
Chalazan B, Freeth E, Mohajeri A, Ramanathan K, Bennett M, Walia J, et al.
Eur J Hum Genet
. 2023 May;
31(7):769-775.
PMID: 37217627
A substantial proportion of atrial fibrillation (AF) cases cannot be explained by acquired AF risk factors. Limited guidelines exist that support routine genetic testing. We aim to determine the prevalence...
5.
Bar-Or A, Montalban X, Hu X, Kropshofer H, Kukkaro P, Coello N, et al.
Neurol Ther
. 2022 Dec;
12(1):303-317.
PMID: 36534274
Introduction: Several studies have described prognostic value of serum neurofilament light chain (sNfL) at the group level in relapsing multiple sclerosis (RMS) patients. Here, we aimed to explore the temporal...
6.
Rothenberger S, Hurdiss D, Walser M, Malvezzi F, Mayor J, Ryter S, et al.
Nat Biotechnol
. 2022 Jul;
40(12):1845-1854.
PMID: 35864170
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with potential resistance to existing drugs emphasizes the need for new therapeutic modalities with broad variant activity. Here we...
7.
Hosseini F, Malhi N, Sellers S, Khan N, Li C, Taylor C, et al.
Can J Cardiol
. 2022 May;
38(10):1570-1579.
PMID: 35568268
South Asians (SAs) experience a higher prevalence and earlier onset of coronary artery disease and have worse outcomes compared with White Caucasians (WCs) following invasive revascularisation procedures, a mainstay of...
8.
Ziemssen T, Arnold D, Alvarez E, Cross A, Willi R, Li B, et al.
Front Immunol
. 2022 Apr;
13:852563.
PMID: 35432382
Objective: This study aims to confirm the prognostic value of baseline serum neurofilament light chain (sNfL) for on-study disease activity and worsening in patients with relapsing MS (RMS). Background: Previous...
9.
Gartner J, Hauser S, Bar-Or A, Montalban X, Cohen J, Cross A, et al.
Mult Scler
. 2022 Mar;
28(10):1562-1575.
PMID: 35266417
Background: In the phase III ASCLEPIOS I and II trials, participants with relapsing multiple sclerosis receiving ofatumumab had significantly better clinical and magnetic resonance imaging (MRI) outcomes than those receiving...
10.
Yu H, Graham G, David O, Kahn J, Savelieva M, Pigeolet E, et al.
CNS Drugs
. 2022 Mar;
36(3):283-300.
PMID: 35233753
Background: Ofatumumab, a fully human anti-CD20 monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (RMS), binds to a unique conformational epitope, thereby depleting B cells very...